Weight Loss Peptides Semaglutide Peptide Lyophilized Powder Semaglutide

• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP, SGS
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >98%
• Hayır. Modeli.: Frazer-Semaglutide
• cas no: 910463 - 68-2
• test yöntemi: yüksek fiyat noktası
• "mod: 1 kg
• görünmeyelim: beyaz liyofilize toz
• raf ömrü: 2 yıl
• depolama: serin ve kuru bir yer
• teslimat: ekspres 5-7 gün içinde elinize ulaşır
• örnek: kullanılabilir
• derece: i̇laç derecesi
• moleküler ağırlık: 4113.57754
• moleküler formül: c187 h291 n45o59
• uygulama: kilo kaybı
• Taşıma Paketi: Foil Bag
• Teknik Özelikler: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Ticari Marka: Frazer
• Menşei: China
• Üretim Kapasitesi: 1000boxes/Month

Ürün Açıklaması

Weight Loss Peptides Semaglutide Peptide Lyophilized Powder Semaglutide

Description

Ry-belsus (semaglutide) is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Ry-belsus is usually given after other diabetes medicines have been tried without success.

The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with overweight and at least one weight-related condition, according to an agency press release.

Weekly semaglutide 2.4 mg (W-egovy, Novo Nordisk), a GLP-1 receptor agonist, is the first-approved drug for chronic weight management in adults with general obesity or overweight since 2014. Semaglutide is indicated for chronic weight management in adults with a BMI of 27 kg/m² or greater who have at least one weight-related comorbidity, such as type 2 diabetes or hypertension, or in adults with a BMI of at least 30 kg/m²

Semaglutide 1 mg injection (O-zempic) was first approved as a treatment for type 2 diabetes in 2017.

Safety and efficacy of semaglutide 2.4 mg was assessed in four 68-week trials. Three were randomized, double-blind, placebo-controlled trials, including 16 weeks of dose increases, and one was a double-blind, placebo-controlled, randomized withdrawal trial in which patients assigned semaglutide either continued treatment or switched to a placebo

Semaglutide 2.4 mg should not be used in combination with other semaglutide-containing products, other GLP-1 receptor agonists or other products intended for weight loss, including prescription drugs, over-the-counter drugs and herbal products, according to the release. Semaglutide 2.4 mg has not been studied in patients with a history of pancreatitis.

This is a once-weekly injectable, which is more tolerable way of managing obesity vs. other treatments. The STEP study data showed semaglutide 2.4 mg crosses the magic threshold of 10% weight loss for many people who received it. This is another tool that will allow clinicians to better manage obesity.

Function

1.Weight loss 
2. Anti-diabetes
3. Alzheimer's disease.
Application

Semaglutide injection (W-egovy) is used along with an individualized low-calorie, low-fat diet and exercise program to help with weight loss in overweight adults who may also have high blood pressure, diabetes, or high cholesterol. Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insuli when blood sugar levels are high. Insuli helps move sugar from the blood into other body tissues where it is used for energy. Semaglutide injection also works by slowing the movement of food through the stomach and may decrease appetite and cause weight loss.